Please sign in to follow a disease.
Could a quick quiz end millions of unnecessary penicillin allergies?
NCT ID NCT05464615
First seen Jul 17, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This study tests whether a short questionnaire can identify hospitalized patients who were incorrectly labeled as allergic to penicillin. Those deemed low-risk receive a supervised dose of amoxicillin to confirm they can tolerate it. If they do, the allergy label is removed from their medical records, potentially improving their future treatment options.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- amoxicillin
- What this could lead to
- If successful, this approach could safely remove penicillin allergy labels for many hospitalized patients, allowing them to receive more effective antibiotics.
- What could go wrong
- This is a small early-phase study, and the questionnaire may not accurately identify all low-risk patients, leading to allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
20 people
The number who actually took part.
- Started
-
Mar 2024
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Hospitalized male or female patients with a history of Penicillin (PCN) allergy or PCN-derivative allergy as reported by patient or documented in Epic * ≥18 years of age * Patients with a medical need for treatment with a PCN or PCN-derivative or other beta-lactam antibiotics as determined by an inpatient provider * Able and willing to provide consent in English. Exclusion Criteria: * History of documented immediate-onset severe allergic reaction or delayed onset hypersensitivity reaction to a PCN or PCN-derivative * Patients who are hemodynamically unstable (e.g., pulse oximetry O2 saturation \<90 %, respiratory rate \>=21 per minute, severe hypoxia requiring non-invasive ventilation, high-flow nasal canula, or mechanical ventilation, refractory hypotension requiring vasopressor support, heart rate \>100 beats per minute, etc.) * Patients with uncontrolled pulmonary diseases (like exacerbation of asthma, Chronic Obstructive Pulmonary Disease (COPD), and/or other forms of chronic lung diseases)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Penicillin allergy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Geisinger Community Medical Center
Scranton, Pennsylvania, 18510, United States
-
Geisinger Lewistown Hospital
Lewiston, Pennsylvania, 17044, United States
-
Geisinger Medical Center
Danville, Pennsylvania, 17822, United States
-
Geisinger Wyoming Valley
Wilkes-Barre, Pennsylvania, 18711, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.